Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Completed 5Not yet recruiting 3Recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Myasthenia Gravis 5

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × rozanolixizumab × Clear all
NCT03971422 2025-12-24

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
200 enrolled 20 charts

Myasthenia Gravis

NCT05681715 2025-11-06

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

UCB Pharma

Phase 3 Completed
62 enrolled 11 charts

Myasthenia Gravis

NCT04650854 2025-04-18

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
165 enrolled 21 charts

Myasthenia Gravis

NCT04124965 2023-09-05

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
71 enrolled 15 charts

Myasthenia Gravis

NCT03052751 2021-08-03

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

UCB Pharma

Phase 2 Completed
43 enrolled 12 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡